drugset / Trial / NCT00546637
Fesoterodine "add-on" Male Overactive Bladder Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
Timeline
- Start
- 2007-11
- Primary completion
- 2009-02
- Completion
- 2009-02
Outcome
Missed primary endpoint
registry p = 0.1959; Mean Difference (Net) -0.4 (95% CI -0.9 to 0.2) NCT00546637 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fesoterodine | Other / unclassified | 4 mg | — |
| Subject | Fesoterodine | Other / unclassified | 8 mg | — |